Beraza-Millor, M.; Rodríguez-Castejón, J.; Miranda, J.; del Pozo-Rodríguez, A.; Rodríguez-Gascón, A.; Solinís, M.Á.
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease. Pharmaceutics 2023, 15, 1936.
https://doi.org/10.3390/pharmaceutics15071936
AMA Style
Beraza-Millor M, Rodríguez-Castejón J, Miranda J, del Pozo-Rodríguez A, Rodríguez-Gascón A, Solinís MÁ.
Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease. Pharmaceutics. 2023; 15(7):1936.
https://doi.org/10.3390/pharmaceutics15071936
Chicago/Turabian Style
Beraza-Millor, Marina, Julen Rodríguez-Castejón, Jonatan Miranda, Ana del Pozo-Rodríguez, Alicia Rodríguez-Gascón, and María Ángeles Solinís.
2023. "Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease" Pharmaceutics 15, no. 7: 1936.
https://doi.org/10.3390/pharmaceutics15071936
APA Style
Beraza-Millor, M., Rodríguez-Castejón, J., Miranda, J., del Pozo-Rodríguez, A., Rodríguez-Gascón, A., & Solinís, M. Á.
(2023). Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease. Pharmaceutics, 15(7), 1936.
https://doi.org/10.3390/pharmaceutics15071936